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ABSTRACT
Introduction Persistent hypercapnic failure in chronic 
obstructive pulmonary disease (COPD) is associated with 
poor prognosis. Long- term home non- invasive ventilation 
is recommended for patients with PaCO2 >7.0 kPa. 
Domiciliary high- flow nasal cannula (HFNC) reduces PaCO2 
in short- term studies. This post- hoc analysis examines 
the effect of HFNC on PaCO2 levels, exacerbations 
and admissions in patients with COPD with persistent 
hypercapnic and hypoxic failures.
Methods The original trial included 74 long- term 
oxygen- treated patients (31 HFNC treated/43 controls) 
with persistent hypercapnic failure (PaCO2 >6 kPa) 
who completed the 12- month study period. Baseline 
data included age, sex, blood gases, exacerbations and 
hospital admissions in the previous year. Data on blood 
gases were also recorded at 6 and 12 months for all 
patients. In addition, acute changes in blood gases after 
30 min of HFNC use at site visits were examined, as were 
exacerbations and hospital admissions during study.
Results Patients were comparable at baseline. After 12 
months there was a 1.3% decrease in PaCO2 in patients using 
HFNC and a 7% increase in controls before HFNC use on 
site (p=0.003). After 30 min of HFNC at visits PaCO2 changed 
significantly, with comparable reductions, at 0, 6 and 12 
months, including for controls who tried HFNC at study end 
(p<0.001). The exacerbation rate increased, compared with 12 
months prestudy, by 2.2/year for controls (p<0.001) and 0.15/
year for HFNC- treated patients (p=0.661). Hospital admission 
rates increased in the control group,+0.3/year from prestudy 
(p=0.180), And decreased by 0.67/year (p=0.013)for HFNC- 
treated patients.
Conclusion This post- hoc analysis indicates that HFNC 
stabilises patients with COPD with persistent hypoxic and 
hypercapnic failures, in terms of PaCO2, exacerbations and 
number of hospitalisations, whereas those not receiving 
HFNC worsened. This suggests that HFNC is a possible 
treatment for patients with persistent hypercapnic COPD.
INTRODUCTION
In patients with chronic obstructive pulmo-
nary disease (COPD), persistent hypercapnic 
respiratory failure is associated with poor 
disease prognosis.1 In COPD, persistent 
hypercapnic failure is a predictor of more 
exacerbations,2 poor quality of life,3 impaired 
cognitive function, especially in combination 
with persistent hypoxic respiratory failure,4 
and mortality.2 In acute hypercapnic respira-
tory failure, treatment with non- invasive 
ventilation (NIV) has been shown to improve 
prognosis,5 and NIV is an established treat-
ment modality in respiratory acute care 
worldwide. The body of evidence for treat-
ment with long- term home NIV (LTH- NIV) 
in persistent hypercapnic respiratory failure 
is growing6–9 and respiratory societies such as 
the European Respiratory Society have made 
guidelines for treatment with LTH- NIV in 
patients with COPD.10
Evidence for the benefit of high- flow nasal 
cannula (HFNC) in patients with COPD with 
persistent hypoxic failure is growing, with 
evidence most positive for its long- term use in 
hypoxemic, frequently exacerbating patients 
with COPD.11–13 In addition, studies have 
shown that PaCO2 levels are reduced with 
short- term and longer- term use of HFNC in 
Key messages
 ► Is high- flow nasal cannula (HFNC) beneficial for pa-
tients with chronic obstructive pulmonary disease 
(COPD) with chronic hypercapnic failure?
 ► HFNC treatment stabilises patients with COPD with 
persistent hypercapnic failure, in terms of prevent-
ing progression in hypercapnia, number of exacer-
bations and hospitalisations.
 ► This study suggests that HFNC is an effective treat-
ment for patients with COPD with persistent hyper-
capnic failure.
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COPD,12 14–16 both in chronic and stable conditions, but 
it has been argued that this is primarily due to a reduc-
tion of CO2 levels in the anatomical dead space.
17 In the 
randomised controlled trial (RCT) by Storgaard et al,12 
hereafter called the Aalborg Study, an inclusion criterion 
was persistent hypoxemic respiratory failure, although 
patients with concomitant hypercapnic respiratory 
failure were not excluded. The patients were comparable 
in terms of all blood gases at inclusion, but for PaCO2 
there was a significant average treatment difference at 12 
months in favour of HFNC treatment.
The aim of this post- hoc analysis is therefore to examine 
further the changes primarily in PaCO2, but also in PaO2 
in patients with persistent hypercapnic and hypoxemic 
respiratory failure over 12 months treatment with HFNC. 
Furthermore, changes in numbers of exacerbations and 
of hospital admission are compared 1 year prior to inclu-
sion and during the study period within the two treat-
ment groups.
METHODS
In the Aalborg Study,12 200 patients with advanced COPD 
and persistent hypoxic failure as demonstrated by three 
consecutive arterial blood gases measured during stable 
conditions18 were randomised to usual care or usual care 
plus HFNC for 12 months. The inclusion process and 
follow- up is described in detail in the Aalborg Study12 and 
therefore is only summarised below.
Inclusion criteria were hypoxemic COPD with long- 
term oxygen therapy (LTOT), prescribed by a Pulmonary 
Medicine specialist, at least 3 months prior to study start. 
Exclusion criteria were malignant disease, terminal non- 
malignant disease other than COPD, unstable psychi-
atric disease or home- treatment with NIV. Persistent 
hypercapnic failure was not an inclusion or exclusion 
criteria. All patients received personalised inhaled medi-
cine according to The Global Inititative for Chronic 
Obstructive Lung Disease (GOLD) recommendations,19 
had previously undergone pulmonary rehabilitation, 
and were in specialised care in connection with LTOT 
treatment, according to the GOLD recommendations.20 
Change of medication and attending rehabilitation were 
allowed, if recommended by the patient’s usual care-
givers, but change of smoking habits during the study 
period would lead to exclusion.
Patients randomised to the HFNC group were treated 
with LTOT plus HFNC home treatment delivered by 
myAIRVO via Optiflow nasal cannula (both Fisher & 
Paykel Healthcare, Auckland, New Zealand) at a recom-
mended flow rate of 20 L/min, 8 hours per day, preferably 
at night; however, there were no restrictions in the dura-
tion of use nor time of day. Blood gases including PaCO2 
were measured using arterial blood gas analysis (ABL 
800 Flex blood gas analyser, Radiometer, Copenhagen, 
Denmark) in both HFNC- treated patients and controls 
at baseline, and at 6- month and 12- month clinic visits. All 
patients allocated to HFNC used HFNC during the clinic 
visits and arterial blood gas analyses were repeated after 
30 min use.
The 200 trial patients included 117 patients with 
concomitant persistent hypercapnic failure (PaCO2 
>6 kPa). Of those 74, (31 treated with HFNC and 43 
controls), completed the 12- month study period and 
were included in this post- hoc analysis. Following the 
initial blood gas analysis at the 12- month close- out visit, 
21 control patients were also treated with HFNC for 
30 min when repeat 30- min arterial blood gas analysis 
was performed, just as was done in the HFNC group at 
0, 6 and 12- month visits. As well as blood gases, baseline 
data collected for all patients included age, sex, body 
mass index, modified Medical Research Council Score 
(mMRC), smoking status, forced expiratory volume in 
the first second (FEV1), percentage of predicted value 
(FEV1%), PaO2 and PaCO2, as well as exacerbations 
and hospital admissions in the previous year. Number 
of exacerbations, hospital admissions during study were 
included.
Baseline data on blood gases were compared statistically 
between groups. Change in PaCO2 over the 12 months 
observational period was investigated with multiple 
regression models. PaCO2 before and after 30 min were 
compared by paired t- tests. Number of exacerbations and 
hospital admissions pre and during study were compared 
with Poisson regression models.
The original RCT was approved by the North Jutland 
Ethical Committee (N-20110057), the Danish Data 
Protection Agency (2008-58-0028) and registered at  Clin-
icalTrials. gov (NCT 02731872). Patients were informed 
according to the Helsinki Declaration and written 
consent was obtained prior to inclusion.
RESULTS
In the HFNC group, the device was used on average 
6.9 hours/day. Baseline data, demonstrated in table 1, 
were comparable, except for mMRC Score, which was 
significantly higher in the HFNC- treated patients.
Figure 1 demonstrates the treatment effect at 12 months 
in HFNC- treated compared with controls, showing that 
the treatment effect was greater with increased baseline 
PaCO2 (p=0.038). By comparison of means, for patients 
with hypercapnia with baseline PaCO2 >6 kPa, the differ-
ential effect was a 1.3% decrease using HFNC (p=0.624), 
compared with an increase of 7% for controls, a differ-
ence significant at p=0.003.
Arterial blood gas values before and after use of 30 min 
of HFNC in HFNC- treated and for controls at each 
visit, baseline, 6 months and 12 months, are shown in 
online supplemental tables S1 and S2). Significant or 
near- significant changes over 12 months in PaO2 were 
similar between groups: controls (ΔPaO2=−0.45 kPa, 
p=0.014); HFNC- treated, (ΔPaO2=−0.31 kPa, p=0.062). 
Over 12 months there was a Δ-standard bicarbonate of 
0.74 mmol/L (p=0.68) in controls and −0.06 mmol/L 
(p=0.73) in HFNC- treated patients.
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Figure 2 shows the relative magnitudes of the immediate 
and long- term changes for PaCO2 which changed signifi-
cantly at all assessments (all p<0.001) after 30 min use of 
HFNC. The changes were consistent in size whether at 0, 
6 or 12 months, including for control patients who tried 
HFNC at study end, and averaged −0.28 kPa or −4.4%.
The exacerbation rate increased, compared with 12 
months prestudy, by 2.2/year for controls (p<0.001) and 
remained stable for HFNC- treated patients (increase of 
0.15/year, p=0.661). There was no significant change 
in hospital admission rates in the control group, +0.3/
year from prestudy (p=0.180), while for HFNC- treated 
patients, the modelled difference between 0 and 
12 months use showed a decrease in hospital admission 
rate of 0.67/year (p=0.013).
DISCUSSION
This post- hoc analysis showed a preventive effect of HFNC 
on progressive hypercapnic respiratory failure, stabilising 
in patients with COPD compared with a PaCO2 increase 
in controls. The magnitude of this difference increased 
for the patients who were more hypercapnic. In addi-
tion, stability was seen in exacerbation rates and decrease 
in hospital admission rates in HFNC- treated patients, 
whereas an increase in exacerbations rates and stability 
in admission rates were seen in controls on usual care.
This is the first analysis to demonstrate the effect of 
long- term use of domiciliary HFNC on arterial blood 
gas CO2 values in patients with persistent hypercapnic 
failure. Previous short- term studies have shown PaCO2 to 
decrease.13–15 21 However, it has been argued that this was 
merely due to a CO2 reduction in the anatomical dead 
space, which has also been simulated in in vitro studies, 
for example by Onodera et al.22 In this current analysis 
a slight long- term reduction in PaCO2 for patients with 
HFNC can be described as stabilisation, in opposition 
to a significant increase in PaCO2 for control patients. 
This contrasts to two LTH- NIV long- term studies, where a 
reduction in mean PaCO2 of 5%–11% was seen, while the 
control group remained stable in the study by Murphy et 
al and actually reduced PaCO2 in the study by Köhnlein 
et al.6 9 However, although comparable in many ways, only 
two- thirds of the patients in both studies suffered from 
Table 1 Baseline characteristics on HFNC- treated patients 
and controls
HFNC
(n=31)
Controls
(n=43)
P 
value
Sex (% female) 68 70 0.90
Age (years) 67 () 68 () 0.88
Active smokers, % 13 14 0.80
BMI 26.6 (8.8) 26.0 (6.2) 0.51
mMRC Score* 3.2 (0.9) 3.7 (0.9) 0.04
Exacerbations 12 
months before 
baseline, n
2.8 (1.9) 2.6 (1.7) 0.42
PaO2, kPa (on LTOT) 9.8 (1.5) 10.0 (1.6) 0.38
Oxygen saturation (%) 95 (2.2) 95 (2.5) 0.57
pH 7.39 (0.03) 7.40 (0.03) 0.76
Standard bicarbonate 
(mmol/L)
30.1 (2.6) 30.3 (2.3) 0.51
Base excess 7.5 (3.6) 7.4 (2.7) 0.81
PaCO2, kPa (on LTOT) 7.3 (1.2) 7.2 (0.6) 0.45
FEV1% 24.5 (8.8) 26.1 (6.2) 0.18
Mean (SD) unless otherwise indicated.
BMI, body mass index; FEV1%, forced expiratory volume in the 
first second, as percentage of expected value; kPa, kilo Pascal; 
LTOT, long- term oxygen therapy; mMRC, modified Medical 
Research Council Score; PaCO2, Partial arterial pressure of carbon 
dioxide; PaO2, Partial arterial pressure of oxygen.
Figure 1 The relationship between change to PaCO2 at 
12 months and baseline values by treatment group.
Figure 2 Development of mean PaCO2over 12 months 
in HFNC and control groups, with change after 30 minutes 
of HFNC treatment also shown at each clinic visit and for 
control patients trying HFNC at study end.
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persistent hypoxemic failure at inclusion.6 9 Hypercapnia 
has previously been recognised as a prognostic marker 
of progressed disease.23–25 The patients in the Aalborg 
Study may therefore have suffered from more progres-
sive disease as they had PaCO2 levels approximately 1 kPa 
higher than control patients in the Murphy et al study. 
In fact, the patients in the Murphy study6 actually had 
PaCO2 levels lower than the current recommended 
threshold for initiating LTH- NIV. The increase in PaCO2 
in the control group in the Aalborg Study is consistent 
with changes previously observed in persistent hyper-
capnic failure which, by nature, is progressive.26 27
In patients with persistent hypercapnic failure the 
central chemoreceptors are resistant to carbon dioxide 
levels in the blood and patients become dependent on 
hypoxic drive.28 Therefore, changes in PaO2 may influ-
ence PaCO2 levels. However, in this analysis no significant 
changes were seen in PaO2 over the 12 months period 
in HFNC- treated patients and in controls a reduction in 
PaO2 was seen, which theoretically should stimulate the 
respiratory drive and reduce PaCO2. There is inconsis-
tency between the two groups, where both reduce O2 
levels, although not significantly in HFNC treated, who 
stabilise PaCO2. On the other hand PaCO2 increase in 
controls, indicating that the effect of the hypoxic drive 
is of minor importance in this matter. In addition, this 
further supports that increased PaCO2 levels in controls 
is a sign of progressive disease and that HFNC treatment 
has a stabilising effect on COPD.
The short- term, 30 min change in PaCO2 with HFNC 
is persistent over the 12- month study and consistent with 
previous findings of reduced hypercapnia as a result 
of a clearing of CO2 from the anatomical dead space.
29 
This PaCO2 reduction is comparable to those seen in the 
previously mentioned studies by Bräunlich and Pisani 
et al which also only demonstrated a short- term reduc-
tion in PaCO2 levels.
14 15 21 Although none of the short- 
term studies have included clinical measures. It has been 
suggested that it may be of clinical importance to patients 
with hypercapnia with tachypnoea;29 however, more 
studies are needed to support this theory.
Persistent hypercapnic failure has been shown to affect 
number of exacerbations negatively2 and exacerbations 
have been shown to be more prevalent and more severe 
in progressed COPD.30 31 In this study, a reduction in 
exacerbation rate was seen in HFNC- treated patients 
with stable PaCO2 levels, although these patients suffered 
from late- stage COPD. Previously, PaCO2 reduction by 
LTH- NIV long- term treatment has been shown to lead to 
reduction in number of exacerbations and a significant 
increase in time to readmission.32 A previous long- term 
study with high- flow treatment of patients with mixed 
obstructive lung diseases showed prolonged time to first 
exacerbation; however, whether patients had persistent 
hypercapnic failure is not described in the paper.33 The 
only other longer study to investigate PaCO2 develop-
ment over a period of HFNC treatment, 12 weeks to be 
exact, reports improvement of health- related quality 
of life, whereas no other clinical significant changes 
were seen.13 Indeed, this post- hoc analysis also shows 
a decrease in hospitalisation rates in HFNC- treated 
patients. A recent meta- analysis by Wilson et al found that 
the effect of LTH- NIV on hospital admissions is sparse; 
however, the number of patients in need of admissions 
reduced.8 The findings of this analysis support the 
conclusion from the work by Bräunlich et al14 16 21 that 
HFNC may be considered for patients with COPD with 
persistent hypercapnic failure, especially if LTH- NIV 
cannot be used. To conclude, this post- hoc analysis of the 
data from the Aalborg 12- month RCT is the first to indi-
cate that not only does HFNC have a stabilising effect on 
the number of exacerbations in patients with COPD with 
combined, persistent hypercapnic and hypoxic failure, 
but, in addition, that HFNC is an alternative add- on to 
LTH- NIV in terms of preventing severe exacerbations, 
which for patients with COPD inevitably is crucial for 
reducing both morbidity and mortality.
This analysis has limitations. It is a post- hoc study, and 
therefore not originally powered for these analyses. In 
addition, it is worth noticing that the patients in this 
study were treated with a flow of 20 L/min. A higher flow 
may have been more beneficial if lowering PaCO2 had 
been the primary target of the study. This is, however, 
the only long- term RCT data available at the moment, 
and therefore important as an indicator and a hypothesis 
generator for future studies.
In conclusion, this study indicates that HFNC stabi-
lises patients with persistent hypoxemic and hypercapnic 
COPD by preventing progression of hypercapnia, and 
also stabilises exacerbations and reduces number of 
hospitalisations, whereas those not receiving HFNC 
worsened over time. This suggests that HFNC is an effec-
tive treatment for patients with persistent hypercapnic 
COPD. As this is a post- hoc analysis this should of course 
be confirmed in future studies.
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